Posted On: 10/31/2016 10:28:37 AM
Post# of 18857
$ARTH +10% bullish today. $ARTH CEO Featured on Publicwire.com ~ Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
FRAMINGHAM, MA--(Marketwired - Aug 19, 2016) - Arch Therapeutics, Inc. ( OTCQB : ARTH ) ("Arch" or the "Company"
, a developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced its President and CEO, Terrence Norchi, MD conducted an interview with Dave Donlin, the host of Publicwire.com's "Small Cap Spotlight" podcast. Dr. Norchi discussed, the Company's lead product candidate, the AC5 Topical Hemostatic Device™ ("AC5" , the results of the Company's recent clinical study of AC5 and its current plans for submitting a CE Mark application, among other topics. The podcast has been posted on the Company's website and is accessible at http://www.archtherapeutics.com/news/media.
Read Full: https://finance.yahoo.com/news/arch-therapeut...00195.html
FRAMINGHAM, MA--(Marketwired - Aug 19, 2016) - Arch Therapeutics, Inc. ( OTCQB : ARTH ) ("Arch" or the "Company"
, a developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced its President and CEO, Terrence Norchi, MD conducted an interview with Dave Donlin, the host of Publicwire.com's "Small Cap Spotlight" podcast. Dr. Norchi discussed, the Company's lead product candidate, the AC5 Topical Hemostatic Device™ ("AC5" , the results of the Company's recent clinical study of AC5 and its current plans for submitting a CE Mark application, among other topics. The podcast has been posted on the Company's website and is accessible at http://www.archtherapeutics.com/news/media. Read Full: https://finance.yahoo.com/news/arch-therapeut...00195.html
(1)
(0)Scroll down for more posts ▼
